Ovid Therapeutics Inc.

NASDAQ:OVID

Biotechnology

Healthcare
$2.26 -4.34%

-$0.11 today

Market cap
$426.53M
Beta
0.18
P/E (TTM)
-7.1
EPS (TTM)
-$0.33
52W Low $0.29High $3.11

Volume 2.16M

Average 3.07M

OVID Pre-Tax Margin

Income before tax as a percentage of revenue.

Ovid Therapeutics Inc.NASDAQ: OVID

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin not reported for Q1 FY2026

Over 3 fiscal years it widened by 3364.5 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-240.1%+4430.0 pp YoY
LTMMar 2026
-339.3%+4217.8 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+4430.0 pp——
3 years+3364.5 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-240.1%
Year-over-year change
+4430.0pp

Pre-Tax Margin vs competitors

How OVID compares with its peers on the latest reported figures

  • OVID's LTM Mar 2026 pre-tax margin of -339.3% is the 6th highest of the 8 companies compared; the peer median is -255.7%.
  • Its year-over-year change of +4217.8 pp is the highest of 7, against a peer median of -171.2 pp.
  • Over three fiscal years its change of +3364.5 pp compares with a peer median of +811.0 pp.
OVID Competitors Peer median
Pre-Tax Margin for OVID and competitors
Company Period LTM level YoY 3-year change
ABEOAbeona Therapeutics Inc.LTM Mar 2026455.6% —+4032.1 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-90.5% +2.2 pp+108.3 pp
MGTXMeiraGTx Holdings plcLTM Mar 2026-151.1% +333.8 pp+673.9 pp
WVEWave Life Sciences Ltd.LTM Mar 2026-255.7% -148.7 pp+3937.7 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-319.3% -193.8 pp-182.8 pp
OVIDOvid Therapeutics Inc.LTM Mar 2026-339.3% +4217.8 pp+3364.5 pp
STOKStoke Therapeutics, Inc.LTM Mar 2026-533.2% -560.2 pp+811.0 pp
TSHATaysha Gene Therapies, Inc.LTM Jun 2026-2728.0% -1583.1 pp+5520.0 pp
NGNENeurogene Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
LXEOLexeo Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding OVID) -255.7%-171.2 pp+811.0 pp

Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue208.38M1.5M392K566K7.25M
Cost of Revenue0000300K
Gross Profit208.38M1.5M392K566K6.95M
Gross Margin100.0%100.0%100.0%100.0%95.9%
Research & Development46.94M24.62M28.59M36.77M25.58M
Selling, General & Admin37.23M32.43M29.59M25.68M24.11M
Operating Expenses84.17M57.05M59.67M62.45M49.39M
Depreciation & Amortization237.08K1.38M568K613K300K
EBITDA124.45M(54.17M)(57.01M)(57.77M)(17.11M)
EBITDA Margin59.7%-3604.5%-14544.1%-10207.1%-236.0%
Operating Income124.21M(55.55M)(59.28M)(61.89M)(42.44M)
Operating Margin59.6%-3696.4%-15122.7%-10933.7%-585.2%
Interest Income004.9M3.9M0
Interest Expense00000
Other Income / Expenses(45.69K)1.38M6.94M35.45M25.03M
Income Before Tax124.16M(54.17M)(52.34M)(26.43M)(17.41M)
Pre-Tax Margin59.6%-3604.7%-13351.8%-4670.1%-240.1%
Income Tax Expense1.33M0000
Net Income122.83M(54.17M)(52.34M)(26.43M)(17.41M)
Net Margin58.9%-3604.7%-13351.8%-4670.1%-240.1%
EPS (Basic)1.78(0.77)(0.74)(0.37)(0.24)
EPS (Diluted)1.76(0.77)(0.74)(0.37)(0.24)
Weighted Avg Shares67.48M70.43M70.58M70.91M73.74M
Weighted Avg Shares (Diluted)68.07M70.43M70.58M70.91M73.74M

Ovid Therapeutics Inc.

NASDAQ:OVID

Intrinsic Alpha fair value

Locked

Current Price

$2.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.